Breaking News, Promotions & Moves

Dr. Franz Haas to Step Down as CEO of CureVac N.V.

Haas will be succeeded by Dr. Alexander Zehnder.

Author Image

By: Charlie Sternberg

Associate Editor

CureVac N.V., a global biopharmaceutical company, has announced that after more than 10 years as a member of the CureVac management board and three years as CEO, Dr. Franz Haas will step down as CEO, effective March 31, 2023. Dr. Alexander Zehnder will succeed Dr. Haas, joining from Sanofi on April 1, 2023.   “The recent clinical validation of the power of CureVac’s proprietary mRNA-technology platform represents an important inflection point to start turning the company into a relevant commer...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters